+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma

Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma

International Journal of Gynecological Cancer 23(1): 81-89

To investigate potential therapeutic targets and prognostic markers for low-grade endometrial stromal sarcoma (LGESS). Thirty-nine patients with LGESS were included in this study. Using tissue microarrays, the immunohistochemical expression levels of 5 therapeutic targets (epidermal growth factor receptor, human epidermal growth factor 2, vascular endothelial growth factor receptor, platelet-derived growth factor receptor [PDGFR], and c-kit) and 3 proteins involved in cell proliferation (p16, p53, and ki67) were investigated. The associations between these targets, markers, other clinicopathological factors, disease-free survival (DFS), and overall survival (OS) were analyzed. Epidermal growth factor receptor and human epidermal growth factor 2 were not expressed in these 39 patients. Vascular endothelial growth factor receptor, PDGFR, c-kit, p16, p53, and ki67 were expressed in 10 (25.6%), 28 (71.8%), 32 (82.1%), 18 (46.2%), 4 (10.3%), and 21 (53.8%) patients, respectively. The expression of each marker was not significantly associated with other clinicopathological factors. On multivariate analysis, p53 and ki67 were associated with significantly poorer DFS and OS. The 5-year DFS rates were 88%, 46%, and 0% for the p53(-)/ki67(-) group (n = 18), p53(-)/ki67(+) group (n = 17), and p53(+)/ki67(+) group (n = 4) (P = 0.002), respectively; the 5-year OS rates were 100%, 71%, and 0%, respectively (P < 0.001). The time to recurrence was longer (P = 0.123), and more patients had distant recurrence in the p53(+)/ki67(+) group (P = 0.063). In patients with LGESS, c-kit and PDGFR were expressed in higher portions of patients, suggesting that imatinib mesylate should be investigated as a potential targeting agent. Both p53 and ki67 demonstrated strong prognostic implications, suggesting that further evaluation using these markers is required.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053701953

Download citation: RISBibTeXText

PMID: 23221606

DOI: 10.1097/igc.0b013e3182738361

Related references

Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. International Journal of Gynecological Pathology 32(3): 299-306, 2013

Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biology 32(3): 451-459, 2011

Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma. Anticancer Research 36(5): 2527-2534, 2016

Metastatic pulmonary nodules of uterine low-grade endometrial stromal sarcoma histopathological and immunohistochemical analysis of 10 cases. 2013

Pulmonary metastatic nodules of uterine low-grade endometrial stromal sarcoma: histopathological and immunohistochemical analysis of 10 cases. Histopathology 63(6): 833-840, 2013

Endometrial stromal sarcoma of low-grade malignancy. Immunohistochemical and three-dimensional reconstruction study with special emphasis on the inadequate terminology of endolymphatic stromal myosis. Acta Pathologica Japonica 39(4): 260-265, 1989

Low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma: a comparative analysis emphasizing the importance of distinguishing between these two groups. International Journal of Surgical Pathology 18(4): 286-291, 2010

High-grade endometrial stromal sarcoma: clinicopathologic and immunohistochemical study of a case. Pathologica 86(2): 217-221, 1994

Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma. Histopathology 62(5): 675-687, 2013

Pulmonary metastases in patients with low-grade endometrial stromal sarcoma. Clinicopathologic findings with immunohistochemical characterization. American Journal of Surgical Pathology 13(2): 133-140, 1989

Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecologic Oncology 92(1): 71-79, 2004

An advanced stage low grade endometrial stromal sarcoma: a therapeutic dilemma. European Journal of Obstetrics Gynecology and Reproductive Biology 115(2): 247-248, 2004

Endometrial low-grade stromal sarcoma with ovarian sex cord-like differentiation: Report of two cases with an immunohistochemical and flow cytometric study. Pathology International 47(6): 412-415, 1997

Transition from low-grade endometrial stromal sarcoma to high-grade endometrial stromal sarcoma. International Journal of Gynecological Pathology 29(4): 374-377, 2010

Immunohistochemical study of high-grade endometrial stromal sarcoma. An autopsy report in comparison with carcinosarcoma, leiomyosarcoma and normal endometrium. Acta Pathologica Japonica 40(4): 301-306, 1990